Your session is about to expire
← Back to Search
BMS-986012 + Chemotherapy + Nivolumab for Small Cell Lung Cancer
Study Summary
This trial will test if a new drug combo is better than current standard of care for a certain type of lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have an autoimmune or inflammatory condition.I have symptoms from cancer spread to my brain or CNS.I have not had chemotherapy, radiation, or biologic therapy for small cell lung cancer.I have a serious heart condition that is not under control.If you want to take part in the PET tracer sub-study, you need to provide a recent tumor biopsy from any location where the cancer is found.I have moderate to severe numbness or tingling in my hands or feet.I need treatment for an immune system condition caused by my cancer.My lung cancer is at an advanced stage and cannot be treated with just radiation.My blood and organs are functioning well.I have a history of specific lung conditions or signs of lung inflammation on a CT scan.I can provide samples of my tumor, unless I'm in the PET tracer study.I have at least one tumor that can be measured on a scan.I am fully active or can carry out light work.
- Group 1: Arm A: Carboplatin + Etoposide + Nivolumab + BMS-986012
- Group 2: Arm B: Carboplatin + Etoposide + Nivolumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there extant studies detailing the efficacy of BMS-986012?
"Currently, there are 1548 ongoing investigations into BMS-986012 with 338 trials being conducted during the third stage. Numerous medical sites in Shanghai alone have initiated studies of this drug; 86028 total locations have active clinical trial programs for it."
What primary condition is BMS-986012 typically utilized to treat?
"BMS-986012 is a commonly prescribed medication for metastatic hepatocellular carcinoma. It also has demonstrated efficacy in treating lymphoma, non-Hodgkin's malignant melanoma of the skin, and Merkel cell cancer."
Are there any ongoing opportunities to join this experiment?
"According to the information accessible on clinicaltrials.gov, this medical trial is currently enrolling participants. It was initially created on March 17th of 2021 and last edited on September 30th 2022."
Has the U.S. Food and Drug Administration sanctioned BMS-986012 for use?
"Our team at Power gives BMS-986012 a 2 rating due to the presence of some data attesting its safety, yet no clinical evidence in support of efficacy."
How many participants are currently involved in this trial?
"For the successful completion of this trial, a total of 120 participants who meet the criteria need to be recruited. The sponsor, Bristol-Myers Squibb is running it from two locations: Local Institution - 0012 in Edmonton, Alberta and MultiCare Health System in Tacoma, Washington."
Are there any Canadian medical centers running this clinical investigation?
"Patients are being accepted at Local Institution - 0012 in Edmonton, Alberta, MultiCare Health System in Tacoma, Washington, and University of Alabama at Birmingham in Birmingham. Additionally there are 18 additional enrolment sites around the continent."
Share this study with friends
Copy Link
Messenger